Subscribe to receive our Event Driven Monitor by email every morning before the market opens.
Editor’s Note: In our last Event Driven Monitor, we mentioned that Surface Oncology (SURF) was to be acquired by Coherus BioSciences (CHRS) for $40 million or $5.2831 per share in cash. This was incorrect.
The way the press release announcing the deal was worded was confusing. We decided to hold off on adding the deal to our Merger Arbitrage Tool until after I had had chance to review the merger agreement. Unfortunately we forgot to remove the update from the Event Driven Monitor.